03/22/23 5:08 PMNasdaq : CNTX earningslow floatContext Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline UpdatesContext Therapeutics Inc. (“Context” or theRHEA-AIneutral
03/15/23 7:30 AMNasdaq : CNTX low floatContext Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company developing novel treatments for solid tumors,RHEA-AIneutral
02/06/23 7:30 AMNasdaq : CNTX clinical triallow floatContext Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial CancerContext Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a company developing novel treatments forRHEA-AIneutral
01/31/23 7:30 AMNasdaq : CNTX fda approvallow floatContext Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast CancerRHEA-AIvery positive
01/09/23 7:30 AMNasdaq : CNTX low floatContext Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersLonza to support the development and manufacturing of CTIM-76, Context’s CLDN6 x CD3 bispecific antibody clinical candidate The bispecific antibody-based therapy is being developed to redirect T-cell mediated lysis toward malignant cells expressing CLDN6 PHILADELPHIA and BASEL, Switzerland, Jan.RHEA-AIneutral
01/04/23 7:30 AMNasdaq : CNTX low floatContext Therapeutics® Highlights 2023 Corporate Priorities and Pipeline MilestonesCTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, Jan. 04, 2023 (GLOBERHEA-AIpositive
12/08/22 7:30 AMNasdaq : CNTX clinical triallow floatContext Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerData presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer trial PHILADELPHIA, Dec.RHEA-AIpositive
11/29/22 7:30 AMNasdaq : CNTX low floatContext Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid TumorsContext Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), aRHEA-AIneutral
11/09/22 4:14 PMNasdaq : CNTX earningslow floatContext Therapeutics® Reports Third Quarter 2022 Operating and Financial ResultsCompany reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR + recurrent endometrial cancer ONA-XR continues to exhibit favorableRHEA-AIneutral
09/27/22 7:30 AMNasdaq : CNTX low floatContext Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developingRHEA-AIpositive